New Advisory Board Member Will Initially Focus On Venowave Sales & Business Development

Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce the Company has added Michael Raimondo, a 30-year veteran in sales and operations within the medical and pharmaceutical industries to its advisory board.

With more than three (3) decades of experience, Mr. Raimondo brings to the table extensive leadership experience including numerous accomplishments in developing industry-leading strategic account organizations that have delivered customer-centric solutions to healthcare systems across the USA. Mr. Raimondo specializes in sales negotiations, which has successfully led to over $500 million in sales contracts.

Michael is a current Board of Advisor for Marketsmith, one of the country's (US) largest woman-owned and operated independent media and marketing agencies. He also is a Managing Partner of The Potentia Group, which specializes in negotiations training, sales leadership development and consulting within the U.S. healthcare market. Michael has a BS in physics and minor in mathematics from Kutztown University, and has served on the board of the Make A Wish Foundation for the Ohio-Kentucky-Indiana region.

"We are pleased that Michael has agreed to join Therma Bright's Advisory Board, where his skills and experience in sales and operations will aid in the Company's sales efforts of its health-tech and med-tech devices, including Venowave," shared Rob Fia, CEO of Therma Bright. "With our Venowave's pending approval on patient reimbursement permanent codes from the U.S. Centers of Medicare and Medicaid (CMS) and a handful of value-added reseller partners ready to engage their medical practitioner networks, we believe Michael will help expand these efforts and open more doors with other reseller partners across the U.S."

"I am excited to join Therma Bright's Advisory Board, and bring my sales, business development and operations experience to the Company," expressed Michael Raimondo. "With over 30 years of experience in medical and pharmaceutical industries, I am confident in my abilities to help grow the Company's value-added resellers across America to bring new, innovative solutions, like Venowave, to patient suffering from various pains and ailments, such as the 900,000 citizens who suffer from deep vein thrombosis each year per the US CDC."

Mr. Raimondo is taking on his advisory role at Therma Bright with great enthusiasm and has already begun actively tapping into his network to introduce Venowave pre-CMS approval.

About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .

FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events and related information such as future sales of Venowave as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.